Journal Article

DZNE-2021-01485

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png The MID1 Protein: A Promising Therapeutic Target in Huntington's Disease.

Heinz, A. ; Schilling, J.DZNE* ; van Roon-Mom, W. ; Krauß, S.

2021
Frontiers Media Lausanne

This record in other databases:    

Please use a persistent id in citations: doi:10.3389/fgene.2021.761714

Abstract: Huntington's disease (HD) is caused by an expansion mutation of a CAG repeat in exon 1 of the huntingtin (HTT) gene, that encodes an expanded polyglutamine tract in the HTT protein. HD is characterized by progressive psychiatric and cognitive symptoms associated with a progressive movement disorder. HTT is ubiquitously expressed, but the pathological changes caused by the mutation are most prominent in the central nervous system. Since the mutation was discovered, research has mainly focused on the mutant HTT protein. But what if the polyglutamine protein is not the only cause of the neurotoxicity? Recent studies show that the mutant RNA transcript is also involved in cellular dysfunction. Here we discuss the abnormal interaction of the mutant HTT transcript with a protein complex containing the MID1 protein. MID1 aberrantly binds to CAG repeats and this binding increases with CAG repeat length. Since MID1 is a translation regulator, association of the MID1 complex stimulates translation of mutant HTT mRNA, resulting in an overproduction of polyglutamine protein. Thus, blocking the interaction between MID1 and mutant HTT mRNA is a promising therapeutic approach. Additionally, we show that MID1 expression in the brain of both HD patients and HD mice is aberrantly increased. This finding further supports the concept of blocking the interaction between MID1 and mutant HTT mRNA to counteract mutant HTT translation as a valuable therapeutic strategy. In line, recent studies in which either compounds affecting the assembly of the MID1 complex or molecules targeting HTT RNA, show promising results.

Keyword(s): Alzheimer’s disease ; CAG repeat ; Huntington’s disease ; MID1 ; RNA-protein interaction ; RNA-targeting drug ; mRNA translation

Note: (CC BY)

---

Contributing Institute(s):

1. Regulatory RNA-protein interaction in neurodegenerative diseases (AG Krauß)

Research Program(s):

1. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Appears in the scientific report 2021

---

Database coverage:
; ; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---